ForPatients
by Roche

Healthy Volunteers

A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02882009 WP39322

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this randomized, open-label, parallel-group, placebo-controlled study is to assess pain following subcutaneous (SC) administration of gantenerumab as a high-concentration liquid formulation (HCLF) at different injection speeds. The total duration of the study for each healthy participant will be up to approximately 21 weeks.

Hoffmann-La Roche Sponsor	**Phase 1** Phase

NCT02882009 WP39322
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 40 Years & <= 80 Years	Accepts Healthy Volunteers